CNBC Daily Open: Tariffs in spotlight — and Trump has a new name for a lake

Trump’s administration is reportedly considering new semiconductor/chip tariffs as lawmakers worry about U.S. firms adopting Chinese AI models, while Nvidia is increasing support for Chinese AI models—keeping the U.S.-China tech race front and center. Geopolitical risks remain elevated (U.S. confirmed it is not in talks with Iran; reports of a secret CIA trip to Moscow warning against NATO attack), pushing oil prices higher. Separately, the FDA approved Gilead’s once-daily HIV pill Bixlenvo to simplify treatment for some patients, and tech earnings (including Nvidia’s) helped lift S&P 500 and Nasdaq overnight.

Analysis

Tariff risk is the cleaner near-term negative for the semiconductor complex than any single earnings beat is positive. The market is implicitly assuming AI demand can outrun policy friction; the more important second-order effect is that every incremental trade barrier raises the all-in cost of AI capex, which is most damaging to second-tier infrastructure names and hardware-adjacent suppliers with less pricing power. NVDA is better insulated than the average semi because it can still monetize software/model compatibility, but the deeper risk is a bifurcated stack that eventually pressures attach rates and China-linked margins over 6-18 months.

SK Hynix’s U.S. buildout is strategically bullish, but the cash flow benefit is long-dated and the real value is political option value: local capacity lowers tariff exposure and improves access to hyperscaler customers that want supply-chain diversification. That should help memory pricing discipline if U.S.-based HBM becomes a scarce strategic asset. The contrarian read is that the market may be underestimating how much this strengthens the hand of the few global memory leaders versus smaller fabs that cannot localize quickly.

GILD’s FDA win is more lifecycle defense than a new growth leg. The key question is switching velocity: if payers and physicians view this as regimen simplification rather than genuine incremental utility, the revenue impact is modest; if it improves persistence, it quietly extends the franchise and raises the probability that lenacapavir becomes a broader platform. Geopolitical escalation is a separate macro tail risk: higher oil and inflation would pressure duration-heavy growth and favor energy as a hedge, but that is a macro overlay rather than a direct company-specific catalyst here.

Key Decisions for Investors

• Tactically buy NVDA on tariff-driven pullbacks over the next 1-3 weeks; the stock should outperform broader semis if policy headlines stay rhetorical rather than punitive. Falsify if margins/guidance show China mix deterioration or if export controls expand beyond tariff noise.
• Avoid chasing the whole semi basket here; if you want exposure, use a relative trade: long NVDA / short SMH for 1-2 months to isolate the strongest AI franchise against policy multiple compression in the sector.
• Buy GILD on weakness for a 1-3 month trade; this is a franchise-defense catalyst, not a step-change growth story. Risk/reward is acceptable if the market gives back the knee-jerk move and then rewards evidence of payer-friendly switching.
• Watch SKHYV as a longer-dated strategic beneficiary of U.S.-based HBM localization, but do not size aggressively until there is clearer evidence of commercial output and utilization; this is a 6-18 month story, not a day-trade.
• If geopolitical headlines push crude materially higher for multiple sessions, add an energy hedge via XLE or USO against growth exposure; the first-order winner is oil, but the second-order loser is long-duration tech multiples.